Back to top
more

Pfizer (PFE)

(Real Time Quote from BATS)

$28.28 USD

28.28
12,679,556

-0.02 (-0.07%)

Updated Nov 1, 2024 11:58 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 23% (58 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Ionis (IONS) Q4 Earnings Decline Y/Y, Sales Beat Estimates

Ionis (IONS) Q4 adjusted earnings decline year over year. The company issues guidance for 2021.

Corcept (CORT) Q4 Earnings In Line, Revenues Miss Estimates

Corcept's (CORT) earnings meet estimates in the fourth quarter of 2020 while revenues miss the same.

The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna and Johnson & Johnson

The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna and Johnson & Johnson

Viatris (VTRS) Declines on Lackluster Outlook, Announces Dividend

Viatris (VTRS) declines after it announces outlook for 2021 and reaffirms strategic commitments.

What's in the Cards for BioNTech (BNTX) This Earnings Season?

On BioNTech's (BNTX) fourth-quarter earnings call, investors are likely to focus on sales number for its COVID-19 vaccine, BNT162b2, which has been developed in partnership with Pfizer.

Kinjel Shah headshot

FDA Issues New Guidelines for COVID-19 Vaccines, Tests, Drugs

The FDA encourages companies to evaluate the impact of COVID-19 virus variants on the efficacy or performance of their COVID-19 vaccines, tests and medicines.

Coronavirus Vaccine Sales Key to Moderna's (MRNA) Q4 Earnings

Investors are likely to focus on Moderna's (MRNA) sales guidance for its coronavirus vaccine in 2021 on the fourth-quarter earrings call.

Pfizer (PFE), BioNTech Test COVID-19 Vaccine in Pregnant Women

Pfizer (PFE) and BioNTech begin dosing in a mid-to-late-stage study on their COVID-19 vaccine in healthy pregnant women.

Kinjel Shah headshot

Pharma Stock Roundup: Coronavirus Vaccine Updates From PFE, AZN & JNJ

WHO authorizes emergency use of AstraZeneca's (AZN) COVID-19 vaccine. J&J (JNJ) seeks conditional approval for its COVID-19 vaccine in EU.

Pfizer/BioNTech to Sell More COVID-19 Vaccine Doses to EU

Pfizer (PFE)/BioNTech (BNTX) win a deal for 200 million more doses of its COVID-19 vaccine in Europe.

J&J (JNJ) Seeks Conditional Nod for COVID-19 Vaccine in EU

J&J's (JNJ) COVID-19 vaccine, if approved, will be the only COVID-19 vaccine to be approved for single administration.

Pfizer (PFE) Gets FDA Nod for New Indication of Immunoglobulin

Pfizer's (PFE) Panzyga gets FDA approval to treat chronic inflammatory demyelinating polyneuropathy (CIDP), a rare neurological disease.

AbbVie (ABBV) Inks CAR T Deal, Gets Botox Label Expansion Nod

AbbVie (ABBV) signs an agreement to research and develop two new CAR-T cell therapies. The FDA approves label expansion of Botox for pediatric patients.

AstraZeneca (AZN) Q4 Earnings, Sales Top Despite COVID-19 Woes

AstraZeneca (AZN) surpasses fourth-quarter estimates on both counts. Stock up in pre-market.

Deciphera (DCPH) Reports Narrower-Than-Expected Q4 Loss

Deciphera Pharmaceuticals (DCPH) reports narrower-than-expected loss. Nonetheless, sales marginally surpass estimates for the fourth quarter of 2020.

Bristol Myers (BMY) Gets European Commission Nod for Inrebic

The European Commission approves Bristol Myers' (BMY) Inrebic for the treatment of adult patients with newly diagnosed and previously treated myelofibrosis.

Novartis (NVS) Gets Breakthrough Therapy Tag for Leukemia Drug

Novartis' (NVS) asciminib gets Breakthrough Therapy tag by the FDA for the treatment of adult patients with Ph+ CML in chronic phase, previously treated with two or more tyrosine kinase inhibitors.

Glaxo's (GSK) Rukobia Gets EU Nod for Multidrug-Resistant HIV

The approval of Glaxo's (GSK) Rukobia is based on data from the pivotal phase III BRIGHTE study. Rukobia was approved in the United States in July last year.

Corcept (CORT) Posts Preliminary '20 Results, Gives 2021 View

Corcept (CORT) provides preliminary revenue figures for fourth-quarter and full-year 2020. The company also issues revenue guidance for 2021. Shares down in after-hours trading.

Cassava (SAVA) Rises on Late-Stage Alzheimer's Study Plans

Cassava (SAVA) provides outline for future study plans on its Alzheimer's disease candidate, simufilam.

The Zacks Analyst Blog Highlights: Google, Pfizer, Uber, Cisco Systems and ConocoPhillips

The Zacks Analyst Blog Highlights: Google, Pfizer, Uber, Cisco Systems and ConocoPhillips

Sweta Killa headshot

Pharma ETFs in Focus Post Q4 Earnings

Healthcare Q4 results seem robust given that it is the fourth-best sector from a revenue growth look and the sixth-strongest in terms of earnings growth.

Sheraz Mian headshot

Top Stock Reports for Alphabet, Pfizer & Uber

Today's Research Daily features new research reports on 16 major stocks, including Alphabet (GOOGL), Pfizer (PFE), and Uber Technologies (UBER).

J&J (JNJ) Seeks Emergency Approval for Coronavirus Vaccine

Johnson & Johnson (JNJ) submits regulatory application to the FDA seeking emergency use approval for its single-shot coronavirus vaccine.

Kinjel Shah headshot

Pharma Stock Roundup: PFE, MRK Q4 Earnings, AZN, JNJ Coronavirus Vaccine Updates

Several companies announce Q4 results. J&J (JNJ) and AstraZeneca (AZN) provide updates on their respective COVID-19 vaccines.